INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investors Meet11-02-2022
11-02-2022
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of Conference Call held on February 02, 202209-02-2022
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investors Meet09-02-2022
Accumulate Indoco Remedies; target of Rs 460: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Indoco Remedies with a target price of Rs 460 in its research report dated February 03, 2022.03-02-2022
Earnings Call for Q3FY22 of Indoco Remedies
Conference Call with Indoco Remedies Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.03-02-2022
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Conference Call held on February 02, 202202-02-2022
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Un-Audited Financial Results for the Quarter and Nine Months ended 31st December, 202102-02-2022
Q3FY22 Quarterly Result Announced for Indoco Remedies Ltd.
Pharmaceuticals company Indoco Remedies declares Q3FY22 result: Indoco’s PAT jumps 31 % in Q3FY22 Indoco Remedies grew by 4.6% at Rs. 348.6 crores, as against Rs. 333.3 crores, same quarter last year. EBIDTA to net sales for the quarter is 21.1% at Rs. 73.4 crores, compared to 18.0% at Rs. 60.0 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 9.5% at Rs. 33.0 crores, compared to 7.5 % at Rs. 25.1 crores, same quarter last year. For 9 month period ended Dec’21, the revenues grew by 19.5% at Rs. 1102.4 crores, as against Rs. 922.6 crores, same period last year. EBIDTA to net sales for the period is 22.4 % at Rs. 246.5 crores, compared to 18.3 % at Rs.169.0 crores, same period last year. For the period, the Profit After Tax to net sales is 10.4% at Rs. 114.1 crores, compared to 7.3% at Rs. 67.5 crores, same period last year. Commenting on the third quarter FY22 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “Good growth in India business coupled with operational efficiency and cost control measures have enabled us to deliver excellent financials this quarter”. Result PDF01-02-2022
INDOCO REMEDIES LTD. - 532612 - Unaudited Results For The Quarter And Nine Months Ended 31St December 2021
Unaudited Results for the Quarter and Nine months ended 31st December 202101-02-2022